Others

Xtalpi’s AI Biology Spin-off INFevo Secures Tens of Millions in Angel Funding to Build Virtual Cell System for Drug Discovery

CompanyDrug

Roche’s Oral SERD Giredestrant Receives FDA Priority Review for Early Breast Cancer Adjuvant Treatment

Others

CSPC Pharmaceutical Receives NMPA Approval for First-in-Class mRNA-LNP Dual-Target CAR-T Therapy SYS 6063 in Systemic Lupus Erythematosus

CompanyDrug

AstraZeneca’s Next-Gen SERD Camizestrant Shows 55% Reduction in Progression Risk and Superior ctDNA Clearance in Phase III SERENA-6 Trial

CompanyDrug

SystImmune and Bristol Myers Squibb’s Dual-Targeted ADC Izalontamabbrengitecan Shows Significant Survival Benefit in Two Phase III Trials

CompanyDrug

CSPC Pharmaceutical’s B7-H3 ADC SYS 6043 Shows 41.8% Response Rate in Phase I Solid Tumor Study

Policy / Regulatory

China’s NMPA Introduces Comprehensive Medical Device Classification Reforms with 2-5 Year Transitional Periods

CompanyDeals

Rallybio to Merge with Avenzo Therapeutics in $215 Million Deal, Creating Pipeline-Rich Entity Focused on Chinese-Origin Oncology Assets

Simcere Pharmaceutical Secures Exclusive Rights to PrimeGenX's Pumecitinib Gel for Atopic Dermatitis in Greater China
CompanyDeals

Simcere Pharmaceutical Secures Exclusive Rights to PrimeGenX’s Pumecitinib Gel for Atopic Dermatitis in Greater China

CompanyDrug

Amgen’s Tarlatamab Receives EC Approval for Extensive-Stage SCLC with 40% Mortality Reduction in Phase III Trial

CompanyDeals

Servier Group Acquires Edgewise Therapeutics’ Muscular Dystrophy Business for Up to $2.65 Billion

CompanyDrug

Alphamab Oncology’s HER3×TROP2 Bispecific ADC JSKN016 Shows 64.5% Response Rate in Triple-Negative Breast Cancer at ASCO 2026